A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)
Clinical trial NCT06186804 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06186804
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-30
- Primary completion
- 2026-10-30
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.